Metformin Tied to Increased Survival in Pancreatic CA Patients

PDAC patients taking metformin had a lower risk of mortality compared to those taking other hypoglycemic meds
PDAC patients taking metformin had a lower risk of mortality compared to those taking other hypoglycemic meds

For pancreatic ductal adenocarcinoma (PDAC) patients with diabetes, metformin treatment was associated with an increase in survival. Those were the findings of a new study published in the American Journal of Gastroenterology.

Researchers analyzed data from the Medicare-related Surveillance, Epidemiology, and End Results registry (SEER), identifying diabetes patients diagnosed with PDAC between 2007 and 2011. Their search found 1,916 patients who were taking hypoglycemic medication for at least 1 year before their cancer diagnosis. 

Related Articles

Results showed that those taking metformin (1,098; 57.3%), had a longer mean survival time than those taking other diabetes medications (818; 42.7%), 5.5 months vs. 4.2 months, respectively (P<0.01). The risk of mortality decreased by 12% for metformin patients after confounders (such as DCSI, Charlson score, and chronic kidney disease) were accounted for (HR, 0.88; 95% CI: 0.81-0.96, P<0.01).

For those on metformin for >2 years before their cancer diagnosis, the hazard ratio (HR) for death was 0.88 (95% CI 0.79–0.98, P=0.02) vs. those not on metformin. For those on metformin for less than 6 months the HR was 0.87 (95% CI 0.75–1.01, P=0.07) vs. those not on metformin.

Differences between the metformin and non-metformin group persisted in the stratified analysis regardless of Charlson score, diabetic complications severity index, or the use of other hypoglycemic medications (P<0.01, in all incidences). Furthermore, the increased survival effect of metformin was identified in both non-metastatic and metastatic disease.

The authors conclude by suggesting further study is needed to confirm their findings. Should they be confirmed, metformin could be recommended as an adjunct to chemotherapy for diabetic PDAC patients.
 
For more information visit Nature.com.



The authors conclude by suggesting further study is needed to confirm their findings. Should they be confirmed, metformin could be recommended as an adjunct to chemotherapy for diabetic PDAC patients.
 
For more information visit Nature.com.


The authors conclude by suggesting further study is needed to confirm their findings. Should they be confirmed, metformin could be recommended as an adjunct to chemotherapy for diabetic PDAC patients.

 

For more information visit Nature.com.

The authors conclude by suggesting further study is needed to confirm their findings. Should they be confirmed, metformin could be recommended as an adjunct to chemotherapy for diabetic PDAC patients.

 

For more information visit Nature.com.

The authors conclude by suggesting further study is needed to confirm their findings. Should they be confirmed, metformin could be recommended as an adjunct to chemotherapy for diabetic PDAC patients.

 

For more information visit Nature.com.

Loading links....